zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
09 juil. 2024 09h00 HE | Zevra Therapeutics
CELEBRATION, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and...
ANEW MEDICAL to Advance Patented Klotho Gene Therapy for Neurodegenerative Disorder Treatments
09 juil. 2024 05h30 HE | ANEW MEDICAL, INC.
ANEW MEDICAL to Advance Patented Klotho Gene Therapy for Neurodegenerative Disorder Treatments
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome
27 juin 2024 08h00 HE | Quoin Pharmaceuticals, Inc.
Clinical site to be Opened in Saudi Arabia       Site Currently Treating Netherton Patients Who Are Eligible for Recruitment into Quoin Studies Experienced Local Clinical Research Organization Has...
ANEW MEDICAL Forms Strategic Partnership with Japan’s Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene
27 juin 2024 05h00 HE | ANEW MEDICAL, INC.
ANEW MEDICAL Forms Strategic Partnership with Japan’s Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene
ANEW MEDICAL, INC. Secures Key Patent in Europe for Human Klotho Gene RNA Slice Variant and Protein
26 juin 2024 05h00 HE | ANEW MEDICAL, INC.
ANEW MEDICAL, INC. SECURES KEY PATENT IN EUROPE FOR HUMAN KLOTHO GENE RNA SLICE VARIANT AND PROTEIN
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference
25 juin 2024 16h05 HE | Quoin Pharmaceuticals, Inc.
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Expands Executive Leadership Team
25 juin 2024 07h30 HE | Zevra Therapeutics
Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Zevra...
novelmed logo.jpg
FDA Approves Phase II Clinical Trial for Ruxoprubart in ANCA Associated Vasculitis (AAV) – a Chronic Rare Disease in Nephrology
17 juin 2024 08h30 HE | NovelMed Therapeutics Inc
-- The United States FDA Clears Initiation of Efficacy Trial in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) Patients A Phase II, Efficacy Trial in adult AAV patients has...
American Kidney Fund
American Kidney Fund Convenes Rare Kidney Disease Action Network to Advocate for Policies and Regulations that Help Patients with Rare Causes of Kidney Disease
13 juin 2024 13h07 HE | American Kidney Fund
ROCKVILLE, Md., June 13, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is proud to announce the launch of the Rare Kidney Disease Action Network (RKDAN), a new effort that will play a...
NMD_Logo3_reg.jpg
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
11 juin 2024 06h00 HE | NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel...